On the stock market since 2020, it operates in the world of money and finance. It has 3,121 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 9% a year over the last 4 years. Every year shown ended in profit.
Executives buying with their own money is usually read as confidence in the company’s future.
The stock trades 16% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 31% — the profit kept from each dollar of revenue is the company’s cushion in hard quarters.
Over the last 12 months, company executives reported 23 buys and 17 sells. Management buying with its own money is usually read as a good sign.
It pays out $1.72 per share each year — regular cash for whoever holds the stock.
Nothing in the current numbers stands out as a clear risk. Still, no stock is ever risk-free.
On our five-subject report card, UCBIO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: UCBIO is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.